Leading startups benefit from BaselArea.swiss
The top 100 startups of Switzerland have been revealed. In Venturelab’s Top 100, the Basel region performs particularly well in the biotech sector, while almost all the Basel companies named have benefited directly or indirectly from BaselArea.swiss.
time for startup (img: Tashatuvango/shutterstock)
Seven companies from the canton of Basel-Stadt and two from the canton of Basel-Landschaft qualified for the Top 100 of Swiss startups. Now, Venturelab has published its latest ranking. Five biotech startups made it into the top 20 – and two of them are from Basel.
Polyneuron Pharmaceuticals AG (14th place) received support from the healthcare accelerator BaseLaunch, which is operated by BaselArea.swiss. The location promotion organization also directly provided services to Cellestia Biotech AG (19th place). With T3 Pharmaceuticals (24th place) and Anaveon AG (37th place) from Bottmingen BL, two other Basel companies supported by BaseLaunch made it into the top 40.
In this year’s top 40 Swiss startups are MaxWell Biosystems (33rd place) and Artidis (36th place). Alongside medtech company Resistell (34th place) from Muttenz BL, they too benefited from BaselArea.swiss. The same goes for the micro- and nanotechnology company Qnami (64th place) from Basel. Internet and mobile company MyCamper (87th place) rounds off the Basel region’s companies in the top 100.
The list is topped by four companies in the electronics/mechanics and medtech sectors. In first place is Lausanne drone provider Flyability, followed by medtech company Lunaphore, which also hails from Lausanne. Two German-Swiss companies are in places 3 and 4 – the Zurich medtech company Ava and flight devices provider Wingtra from Zug. The best biotech company in the ranking is Cutiss AG from Zurich in 6th place.
Share this article
You might also be interested in
A research project is investigating the improvement in the condition of patients who have been hospitalized due to COVID-19. docdok.health based in Basel is contributing the smartphone app for the project.Read More
The Allschwil-based pharmaceutical company Idorsia receives a payment of 45 million US dollars as part of an agreement with Neurocrine Biosciences and shall also be entitled to claim milestone payments in future. Neurocrine has exercised a licensing option for a drug developed by Idorsia to treat epilepsy..Read More
Roche has received Emergency Use Authorization in the USA for an antibody test in connection with the novel coronavirus. The tests are already being distributed around the world. In May, production capacities are to already be scaled up to the high double-digit million area.Read More
Basel is valued as a location for company headquarters. In a rating from the fDi Intelligence platform of the Financial Times, Basel achieves eighth place in Europe. No other Swiss city does better.Read More
The investment and innovation promotion agency Basel Area Business & Innovation, previously known as BaselArea.swiss, can look back on a successful year in 2019. In this regard, positive developments in the healthtech sector and in Switzerland Innovation Park Basel Area stand out.Read More
The University Hospital Basel is the first Swiss hospital to have treated two Covid-19 patients with the plasma from a patient who has recovered from the virus, which means that they are receiving the appropriate antibodies. This method is a potential therapeutic option.Read More